C14orf2 | Chromosome 14 open reading frame 2 | Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
C18orf32 | Chromosome 18 open reading frame 32 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
C2orf82 | Chromosome 2 open reading frame 82 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C5orf60 | Chromosome 5 open reading frame 60 | Predicted membrane proteins
| | | | | Tissue enriched |
C9orf69 | Chromosome 9 open reading frame 69 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CA12 | Carbonic anhydrase XII | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNG8 | Calcium channel, voltage-dependent, gamma subunit 8 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CADM1 | Cell adhesion molecule 1 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
CADM2 | Cell adhesion molecule 2 | Predicted membrane proteins
| | | | | Tissue enriched |
CADM3 | Cell adhesion molecule 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
CADM4 | Cell adhesion molecule 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
CAMK2A | Calcium/calmodulin-dependent protein kinase II alpha | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CAMK2B | Calcium/calmodulin-dependent protein kinase II beta | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CANT1 | Calcium activated nucleotidase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CANX | Calnexin | Cancer-related genes Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CASK | Calcium/calmodulin-dependent serine protein kinase (MAGUK family) | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CATSPER4 | Cation channel, sperm associated 4 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
CATSPERD | Catsper channel auxiliary subunit delta | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CAV2 | Caveolin 2 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CAV3 | Caveolin 3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
CCDC51 | Coiled-coil domain containing 51 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CCDC90B | Coiled-coil domain containing 90B | Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CCR6 | Chemokine (C-C motif) receptor 6 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CD151 | CD151 molecule (Raph blood group) | Blood group antigen proteins CD markers Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
CD163 | CD163 molecule | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CD163L1 | CD163 molecule-like 1 | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD164L2 | CD164 sialomucin-like 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD19 | CD19 molecule | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CD1A | CD1a molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD207 | CD207 molecule, langerin | CD markers Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CD209 | CD209 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD226 | CD226 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD276 | CD276 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CD300LF | CD300 molecule-like family member f | CD markers Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD34 | CD34 molecule | CD markers Predicted membrane proteins
| | | | | Expressed in all |
CD36 | CD36 molecule (thrombospondin receptor) | Cancer-related genes CD markers Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |